Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2023-04-26 Declaration of Voting R…
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 25, 2023, reporting the results of the 2023 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. It details the voting outcomes on director elections, ratification of the independent auditor, and a shareholder proposal. The content focuses on the submission of matters to a vote of security holders and the official voting results. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 6106 characters, which is sufficient to contain detailed voting results rather than just an announcement of a report. Therefore, the correct classification is DVA with high confidence.
2023-04-26 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It discusses recommendations from proxy advisory firms ISS and Glass Lewis regarding voting on director nominees for the company's upcoming Annual Meeting. The document urges shareholders to vote on the WHITE proxy card and provides detailed information about the proxy solicitation and voting process. It is not the proxy statement itself but rather definitive additional materials related to the proxy solicitation. The content focuses on governance and shareholder voting matters, which aligns with Proxy Solicitation & Information Statement filings. The document is not an annual report, earnings release, or other financial report, but specifically proxy solicitation materials. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2023-04-17 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It is titled 'Definitive Additional Materials' related to a proxy statement for Zevra Therapeutics, Inc. Proxy statements and related materials are used to provide information to shareholders to solicit votes for meetings. This matches the description of Proxy Solicitation & Information Statement (PSI). The document length is short (1252 characters) and it is clearly a filing of proxy materials, not an annual report or other financial report. Therefore, the correct classification is PSI.
2023-04-05 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It references a definitive proxy statement and additional materials related to the solicitation of proxies for the 2023 Annual Meeting of Stockholders. The text includes information about board nominees and instructions for investors to read the proxy statement. It explicitly states it is not a substitute for the proxy statement but additional materials. The document length is 3544 characters, which is relatively short and consistent with additional proxy solicitation materials rather than a full proxy statement. The document is not the full proxy statement itself but additional definitive materials related to the proxy solicitation. According to the filing definitions, proxy solicitation and information statements are classified under code PSI. Therefore, this document is best classified as Proxy Solicitation & Information Statement (PSI).
2023-04-03 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It references solicitation of proxies for the 2023 Annual Meeting of Stockholders and includes additional materials related to the proxy statement. The text explicitly states it is "Definitive Additional Materials" to a proxy statement and urges investors to read the proxy statement filed on Schedule 14A. The document does not contain financial statements or detailed financial data but is focused on proxy solicitation and shareholder voting information. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 3550 characters, which is consistent with additional proxy materials rather than a full annual report or other financial filings.
2023-03-30 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the appointment of a new director to the board, including detailed biographical information and terms of service. This fits the description of announcements related to changes in the company's board of directors or senior management. The document is not a full annual report, earnings release, or other financial report, but specifically an announcement of a board change. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and content support this classification with high confidence.
2023-03-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.